Ascendis Pharma A/S(ASND)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Ascendis Pharma A/S (ASND) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ASND at 44.8/100 on a 32-signal composite quality model, placing it at rank #1,898 of 2,961 stocks — the bottom half of the AI-ranked universe. ASND scores in the top quartile across revenue growth (95.1). Areas of concern include institutional flow (2.0) and balance sheet strength (11.0), which score below median versus the broader universe. Top institutional holders of ASND by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Avoro Capital Advisors, based on the most recent SEC filings. ASND trades on the Nasdaq exchange and files with the SEC under CIK 1612042. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ASND daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ascendis Pharma A/S directly from SEC EDGAR.

AI Quality Score

44.8/100

AI Rank

#1,898

ASND key financials by period

Ascendis Pharma A/S reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202520-F$720.1M
FY 202420-F$363.6M
FY 202320-F$266.7M
FY 202220-F$51.2M
FY 202120-F$7.8M
FY 202020-F$7.0M

Institutions holding ASND

Institutional investors reporting a position in Ascendis Pharma A/S on SEC Form 13F.
InstitutionSharesValueReported
RA CAPITAL MANAGEMENT, L.P.10,281,496$2.7B2026-06-30
T. Rowe Price Investment Management6,754,846$1.8B2026-06-30
Avoro Capital Advisors5,111,111$1.4B2026-06-30
WESTFIELD CAPITAL MANAGEMENT4,798,267$1.3B2026-06-30
Jupiter Topco3,648,772$973.4M2026-06-30
FMR3,545,575$945.7M2026-06-30
Artisan Partners Limited Partnership2,634,024$702.5M2026-06-30
BlackRock2,211,833$589.9M2026-06-30
Capital International Investors1,988,614$530.4M2026-06-30
MASSACHUSETTS FINANCIAL SERVICES1,875,301$500.1M2026-06-30
ASND

Ascendis Pharma A/S

ASND
NasdaqLarge CapHealthcare

13F Pro Quality Score

44.8/100

Rank #1,898 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

95.1/100

Profitability

14.3/100

Balance Sheet

11.0/100

Earnings Quality

30.0/100

Free Cash Flow

30.0/100

Institutional Flow

2.0/100

Revenue Scale

43.5/100

Dilution Risk

94.7/100

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Financial metrics will appear once SEC EDGAR data is ingested for this company.

Top Institutional Holders

as of Q2 2026
$18.09B total

Financial Trends

Revenue & Net Income

Loading ratio trend…